Xbrane Biopharma AB (STU:7XB0) Interest Expense: €-0.57 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7XB0 Xbrane Biopharma AB STU:7XB0
51 GF Score
Price €0.75
GF Value €0.51
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB Interest Expense?

Xbrane Biopharma AB STU:7XB0 -2.85% 51 Interest Expense is €-0.57 Mil as of Jun. 2026. GuruFocus rates STU:7XB0 with a GF Score™ of 51/100 and a GF Value™ of €0.51 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Xbrane Biopharma AB's interest expense for the three months ended in Jun. 2026 was € -0.21 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.57 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Xbrane Biopharma AB's Operating Income for the three months ended in Jun. 2026 was € -0.82 Mil. Xbrane Biopharma AB's Interest Expense for the three months ended in Jun. 2026 was € -0.21 Mil. Xbrane Biopharma AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Xbrane Biopharma AB  (STU:7XB0) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Xbrane Biopharma AB's Interest Expense for the three months ended in Jun. 2026 was €-0.21 Mil. Its Operating Income for the three months ended in Jun. 2026 was €-0.82 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was €0.27 Mil.

Xbrane Biopharma AB's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Xbrane Biopharma AB did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Xbrane Biopharma AB Interest Expense Historical Data

* Premium members only.

The historical data trend for Xbrane Biopharma AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xbrane Biopharma AB Interest Expense Chart

Xbrane Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.26 -0.24 -1.65 -2.66 -1.11

Xbrane Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.02 -0.14 -0.20 -0.21
STU:7XB0
51GF Score
Xbrane Biopharma AB STU:7XB0
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.57 Mil mean?
Xbrane Biopharma AB (STU:7XB0) has a Interest Expense of €-0.57 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's Interest Expense too high?
Xbrane Biopharma AB's current Interest Expense is €-0.57 Mil. Overall, Xbrane Biopharma AB has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Interest Expense compare to VRTX and REGN?
Xbrane Biopharma AB's Interest Expense of €-0.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current Interest Expense is €-0.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (STU:7XB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.51, compared to a current price of €0.75 — trading 47.1% above its estimated fair value. The current Interest Expense is €-0.57 Mil. Xbrane Biopharma AB's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Xbrane Biopharma AB (STU:7XB0), the current Interest Expense is €-0.57 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (STU:7XB0) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of €0.75 is trading 47.1% above its estimated GF Value™ of €0.51. GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.

Key valuation signals for STU:7XB0:

  • Interest Expense: €-0.57 Mil
  • GF Value™: €0.51 vs. price of €0.75 (47.1% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the STU:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Other Exchanges XBRANE:Sweden7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
51GF Score

Get the complete analysis for STU:7XB0

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price
€0.51
GF Value